Background Poorly differentiated thyroid carcinoma (PDTC) accounts for a small portion of thyroid carcinomas but contributes to a significant proportion of thyroid carcinoma-associated deaths. The clinicopathological prognostic factors and clinical outcomes of PDTC remain unclear. We aimed to evaluate the clinical outcomes of patients with PDTC after curative treatment.
Methods A comprehensive search was performed up to September 2023. We included studies investigating treatment outcomes in patients with PDTC who underwent initial surgery. The 5-year disease-free survival (DFS) and overall survival (OS) were extracted. In this meta-analysis, the enrolled PDTC histological criteria included 3rd, 4th, and 5th World Health Organization (WHO) and Memorial Sloan Kettering Cancer Center (MSKCC) classification. A random-effects model was used for the pooled proportion analysis. Meta-regression analysis was conducted to evaluate the prognostic factors.
Results Twenty retrospective studies published between 2007 and 2023, including 1,294 patients, met all inclusion criteria. Studies that diagnosed PDTC based on various histological criteria including 3rd WHO (n=5), 4th WHO (n=12), 5th WHO (n=2), and MSKCC (n=1) were included. Overall, 5-year DFS and 5-year OS were 49.4% (95% confidence interval [CI], 42.3 to 56.4) and 73.8% (95% CI, 66.5 to 79.9), with moderate heterogeneity of 58% and 55%, respectively. In meta-regression analysis, extrathyroidal extension (ETE) was a prognostic factor for OS.
Conclusion The meta-analysis of DFS and OS in patients with PDTC show the moderate heterogeneity with a variety of histological criteria. ETE appears to have a significant impact on OS, regardless of histological criteria.
Citations
Citations to this article as recorded by
Differentiated high-grade thyroid carcinoma (DHGTC): clinicopathological analysis of a new entity in a chilean center Marlín Solórzano, Ignacio Fuentes, José Miguel González, Nicole Lustig, Lorena Mosso, Joel Falcón, Catalina Ruiz, Joaquín Viñambres, Rodolfo Cabello, Hernán González, Pablo H Montero, Francisco Cruz, Rodrigo Jaimovich, Juan Carlos Quintana, Antonieta Sola Endocrine.2026;[Epub] CrossRef
Poorly differentiated thyroid carcinoma in identical twins: a report of two cases and review of the literature Amal El Masri, Celine El Moughrabi, Anas El Zouhbi, Anthony Shebly, Hala Kassouf, Mustafa Natout, Yusef Hazimeh, Mustapha El Lakis Thyroid Research.2026;[Epub] CrossRef
Clinical and prognostic characteristics of poorly differentiated thyroid carcinomas B.B. Guda, A.V. Tymkiv, M.V. Ostafiychuk, I.I. Komisarenko, I.V. Gamezardashvili, M.D. Melnik INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(2): 111. CrossRef
Multilayered Insights into Poorly Differentiated, BRAFV600E-Positive, Thyroid Carcinoma in a Rapidly Developing Goiter with Retrosternal Extension: From En “Y” Cervicotomy to SPECT/CT-Positive Lung Metastases Oana-Claudia Sima, Anca-Pati Cucu, Dana Terzea, Claudiu Nistor, Florina Vasilescu, Lucian-George Eftimie, Mihai-Lucian Ciobica, Mihai Costachescu, Mara Carsote Diagnostics.2025; 15(16): 2049. CrossRef
GDF15 is associated with thyroid cancer progression and may modulate thyroid cancer cell senescence in a p53-dependent manner Jingyu Ma, Zishuo Liu, Rui Hua, Changyuan Ding, Zhenpeng Yang, Weili Liang, Bin Lv Frontiers in Endocrinology.2025;[Epub] CrossRef
Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis) Mihai Costachescu, Nina Ionovici , Dana Cristina Terzea , Florina Vasilescu , Lucian-George Eftimie , Alexandra-Ioana Trandafir , Ana-Maria Gheorghe , Oana-Claudia Sima , Claudiu Nistor , Mara Carsote Romanian Journal of Morphology and Embryology.2025; 66(3): 431. CrossRef
Aggressive Types of Malignant Thyroid Neoplasms Maria Boudina, Eleana Zisimopoulou, Persefoni Xirou, Alexandra Chrisoulidou Journal of Clinical Medicine.2024; 13(20): 6119. CrossRef